top of page
.png)
Supported projects
LiveRNA
Develops first-in-class drug targeting cGAS and using mRNA technology to stimulate innate immunity. By activating the STING pathway, this approach boosts the immune response against cancers and other pathologies, particularly in patients refractory to conventional treatments. Using virus-like particles (VLPs), this technology stimulates cytokine production and boosts immune cell response.
PSCC's entrance
March 2026
Localization
FR - Île-de-France
Modality
Immunotherapy
Development status
Biotech - Lead optimization
Award(s)
iLAB
bottom of page

